T7681

AZD-5069 is an chemokine receptor 2 antagonist (CXCR2; IC50 = 0.79 nM).

Ganitumab (AMG 479) is a highly potent monoclonal antibody targeting the type 1 insulin-like growth factor receptor (IGF1R). Recognized for binding IGF1R at low concentrations with a KD value of 0.22 nM, Ganitumab inhibits IGF1R interactions with IGF1 and IGF2 in mice, making it useful for cancer research.

Imgatuzumab (RG 7160; GA201) is a humanized, glycoengineered IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This product inhibits EGFR-mediated signaling (such as MAPK and PI3K pathways) by blocking EGF binding and inducing receptor internalization. As a glycoengineered antibody, Imgatuzumab features enhanced affinity for Fc gamma RIIIa, resulting in potent antibody-dependent cellular cytotoxicity (ADCC). It is used to research EGFR-overexpressing solid tumors and demonstrates synergistic effects when combined with chemotherapeutic agents.

Intetumumab (CNTO 95) is a fully human anti-α(v)-integrin monoclonal antibody that is a radiosensitizer in xenograft tumor-bearing mice, inhibits tumor growth, and reduces lung metastases in the A549 NSCLC xenograft model.

Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) engineered to target nerve growth factor (NGF). Bedinvetmab prevents NGF from binding its receptors, tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR). Bedinvetmab is primarily utilized in osteoarthritis research, where it is studied for its ability to manage pain in canine models.

Lampalizumab (RG 7417) is a humanized monoclonal antibody targeting Complement Factor D in the complement pathway, used in age-related macular degeneration (AMD) and cardiovascular disease research.

Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM).

Lokivetmab, an Anti-Canine IL31 Recombinant Antibody, is a monoclonal antibody targeting canine IL-31, utilized in research related to atopic dermatitis (AD) in dogs [1].

Lulizumab, a humanized anti-CD28 recombinant antibody, functions as a selective CD28 blockade. By specifically targeting CD28 signaling, it inhibits T cell activation [1].

Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity for the study of advanced HER3-positive solid tumors and breast cancer.

Metelimumab (CAT-192) is a humanised monoclonal antibody targeting TGFβ1, which can be used to study diffuse systemic sclerosis (d-SSc).